Who Pays My Doctor?

Healthcare provider profile · identity verified

Roger Rivera, DNP

Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Psychiatric/Mental Health · KISSIMMEE, FL · NPI 1730697715

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Roger Rivera, DNP received $489,884.66 in general payments during 2025 across 615 reported records.

ABBVIE INC. accounted for 30.1% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 14 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Auvelity, Caplyta, Fanapt, Ingrezza, Lybalvi, Vraylar.

ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Vraylar by this doctor in 2024.

Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LYBALVI as an associated drug or biological on 93784 records involving 20135 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Lybalvi by this doctor in 2024.

Axsome Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Auvelity as an associated drug or biological on 116023 records involving 35298 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Auvelity by this doctor in 2024.

ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Caplyta by this doctor in 2024.

Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Caplyta as an associated drug or biological on 11 records involving 9 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Caplyta by this doctor in 2024.

Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Ingrezza by this doctor in 2024.

Vanda Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FANAPT as an associated drug or biological on 95605 records involving 21383 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Fanapt by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$489,884.66

615 reported records · 10 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported companyCanonical companyAmountShareRecordsYear
ABBVIE INC. Unresolved — no canonical attribution shown $147,652.7030.1%1552025
Vanda Pharmaceuticals Inc. Unresolved — no canonical attribution shown $109,886.9022.4%1482025
Axsome Therapeutics, Inc. Unresolved — no canonical attribution shown $73,442.3315.0%1122025
Neurocrine BioSciences, Inc. Unresolved — no canonical attribution shown $59,214.8412.1%622025
Alkermes, Inc. Unresolved — no canonical attribution shown $37,763.297.7%482025
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Unresolved — no canonical attribution shown $23,425.864.8%362025
E.R. Squibb & Sons, L.L.C. Unresolved — no canonical attribution shown $19,475.774.0%352025
Teva Pharmaceuticals USA, Inc. Unresolved — no canonical attribution shown $17,381.993.5%132025
Otsuka America Pharmaceutical, Inc. Unresolved — no canonical attribution shown $1,548.240.3%32025
Janssen Pharmaceuticals, Inc Unresolved — no canonical attribution shown $92.740.0%32025

What were the payments for?

Payment categories

CategoryAmountRecords
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program$283,646.00141
Travel and Lodging$132,924.40204
Honoraria$49,891.0035
Food and Beverage$12,430.76229
Consulting Fee$10,992.506

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported productTypeReported companyRelated amount*RecordsYear
VRAYLAR
Normalized: vraylar		 Drug ABBVIE INC. $147,652.70 155 2025
Source payment records
FANAPT
Normalized: fanapt		 Drug Vanda Pharmaceuticals Inc. $109,886.90 148 2025
Source payment records
Auvelity
Normalized: auvelity		 Drug Axsome Therapeutics, Inc. $73,417.12 110 2025
Source payment records
INGREZZA
Normalized: ingrezza		 Drug Neurocrine BioSciences, Inc. $59,214.84 62 2025
Source payment records
LYBALVI
Normalized: lybalvi		 Drug Alkermes, Inc. $37,313.29 47 2025
Source payment records
CAPLYTA
Normalized: caplyta		 Drug ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $23,425.86 36 2025
Source payment records
COBENFY
Normalized: cobenfy		 Drug E.R. Squibb & Sons, L.L.C. $19,475.77 35 2025
Source payment records
UZEDY
Normalized: uzedy		 Drug Teva Pharmaceuticals USA, Inc. $17,367.97 12 2025
Source payment records
VIVITROL
Normalized: vivitrol		 Drug Alkermes, Inc. $450.00 1 2025
Source payment records
SPRAVATO
Normalized: spravato		 Drug Janssen Pharmaceuticals, Inc $92.74 3 2025
Source payment records
REXULTI
Normalized: rexulti		 Drug Otsuka America Pharmaceutical, Inc. $48.24 2 2025
Source payment records
ARISTADA
Normalized: aristada		 Drug Alkermes, Inc. $38.94 1 2025
Source payment records
Symbravo
Normalized: symbravo		 Drug Axsome Therapeutics, Inc. $25.21 2 2025
Source payment records
AUSTEDO XR
Normalized: austedo xr		 Drug Teva Pharmaceuticals USA, Inc. $14.02 1 2025
Source payment records

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments productPayment yearPart D brandPart D yearClaimsMatch methodSource
Auvelity
auvelity		 2025 Auvelity 2024 30 exact normalized Medicare Part D
CAPLYTA
caplyta		 2025 Caplyta 2024 24
Beneficiary count suppressed		 exact normalized Medicare Part D
FANAPT
fanapt		 2025 Fanapt 2024 30
Beneficiary count suppressed		 exact normalized Medicare Part D
INGREZZA
ingrezza		 2025 Ingrezza 2024 22
Beneficiary count suppressed		 exact normalized Medicare Part D
LYBALVI
lybalvi		 2025 Lybalvi 2024 56 exact normalized Medicare Part D
VRAYLAR
vraylar		 2025 Vraylar 2024 65 exact normalized Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying companyPayment yearDrug reported by same entityOpen Payments evidencePart DClaimsBeneficiaries
ABBVIE INC.
Exact reporting entity; no affiliate inference		 2025 VRAYLAR
open payments reported associated product		 CMS Open Payments — General Payments
377741 supporting records · 62704 recipient NPIs · example record 1201352550 		Vraylar · 2024
Exact normalized brand match · 1 Part D row		 65 18
Alkermes, Inc.
Exact reporting entity; no affiliate inference		 2025 LYBALVI
open payments reported associated product		 CMS Open Payments — General Payments
93784 supporting records · 20135 recipient NPIs · example record 1222428566 		Lybalvi · 2024
Exact normalized brand match · 1 Part D row		 56 14
Axsome Therapeutics, Inc.
Exact reporting entity; no affiliate inference		 2025 Auvelity
open payments reported associated product		 CMS Open Payments — General Payments
116023 supporting records · 35298 recipient NPIs · example record 1235293064 		Auvelity · 2024
Exact normalized brand match · 1 Part D row		 30 11
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)
Exact reporting entity; no affiliate inference		 2025 CAPLYTA
open payments reported associated product		 CMS Open Payments — General Payments
211855 supporting records · 46143 recipient NPIs · example record 1241243071 		Caplyta · 2024
Exact normalized brand match · 1 Part D row		 24 suppressed by CMS
Janssen Pharmaceuticals, Inc
Exact reporting entity; no affiliate inference		 2025 Caplyta
open payments reported associated product		 CMS Open Payments — General Payments
11 supporting records · 9 recipient NPIs · example record 1174547314 		Caplyta · 2024
Exact normalized brand match · 1 Part D row		 24 suppressed by CMS
Neurocrine BioSciences, Inc.
Exact reporting entity; no affiliate inference		 2025 INGREZZA
open payments reported associated product		 CMS Open Payments — General Payments
126456 supporting records · 27390 recipient NPIs · example record 1242766729 		Ingrezza · 2024
Exact normalized brand match · 1 Part D row		 22 suppressed by CMS
Vanda Pharmaceuticals Inc.
Exact reporting entity; no affiliate inference		 2025 FANAPT
open payments reported associated product		 CMS Open Payments — General Payments
95605 supporting records · 21383 recipient NPIs · example record 1232940535 		Fanapt · 2024
Exact normalized brand match · 1 Part D row		 30 suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

BrandGenericClaimsBeneficiaries
VraylarCariprazine Hcl6518
AlprazolamAlprazolam6117
LybalviOlanzapine/Samidorphan Malate5614
Duloxetine HclDuloxetine Hcl4212
ClonazepamClonazepam3912
Sertraline HclSertraline Hcl39suppressed
Quetiapine FumarateQuetiapine Fumarate35suppressed
AuvelityDextromethorphan Hbr/Bupropion3011
FanaptIloperidone30suppressed
Venlafaxine Hcl ErVenlafaxine Hcl28suppressed
CaplytaLumateperone Tosylate24suppressed
Hydroxyzine HclHydroxyzine Hcl24suppressed
IngrezzaValbenazine Tosylate22suppressed
Zolpidem TartrateZolpidem Tartrate18suppressed
Bupropion XlBupropion Hcl17suppressed
Trazodone HclTrazodone Hcl17suppressed
Escitalopram OxalateEscitalopram Oxalate16suppressed
Fluoxetine HclFluoxetine Hcl16suppressed
LamotrigineLamotrigine16suppressed
QuviviqDaridorexant Hcl15suppressed
Bupropion Hcl SrBupropion Hcl13suppressed
LorazepamLorazepam13suppressed
Metformin HclMetformin Hcl12suppressed
AripiprazoleAripiprazole11suppressed
BelsomraSuvorexant11suppressed
Lurasidone HclLurasidone Hcl11suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

YearGeneral PaymentsMain payerExplicit productsCompany overlapsPart D coverage
2025 $489,884.66 · 615 records ABBVIE INC. ARISTADA, AUSTEDO XR, Auvelity, CAPLYTA, COBENFY, FANAPT, INGREZZA, LYBALVI, REXULTI, SPRAVATO, Symbravo, UZEDY, VIVITROL, VRAYLAR 7 —
2024 — — — — Complete

Questions to ask

Questions you could discuss with your doctor

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Loaded source releases

DatasetYearPublicationSource
CMS Open Payments — General Payments 2025 2026-06-30 Original source
Medicare Part D Prescribers by Provider and Drug 2024 2026-05-06 Original source
NPPES Data Dissemination V2 current / reference data 2026-08-10 Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error